Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The two-drug regimen can cure the virus in as little as eight weeks.
Real-world results of eight weeks of the hepatitis C virus treatment Harvoni (ledipasvir/sofosbuvir) are excellent.
Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.
The status was granted to the investigational pangenotypic hep C fixed-dose combination tablet of Sovaldi/velpatasivr.
Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.
Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and...
The FDA has approved new indications for Gilead’s Harvoni: to treat hepatitis C in those with genotypes 4Ã¢€“6 of the virus and in those...
Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of...
The real-world cure rates offered by Sovaldi (sofosbuvir)-based hep C virus regimens have not been as good as those seen in clinical trials
A look at real-world use of Bristol-Myers Squibb’s Daklinza (daclatasvir) and Gilead Sciences’ Sovaldi (sofosbuvir) showed that, among those c...
The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among...
The American Association for the Study of Liver Diseases has updated the treatment guidelines for hepatitis C.
Once you’ve officially rid yourself of hepatitis C, how certain can you be that the virus is gone for good?
Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...
Eight weeks of daclatasvir and Sovaldi cured hepatitis C in 76 percent of people coinfected with HIV in a recent trial, including all of those...
Highlights from the 50th Annual Meeting of the European Association for the Study of the Liver.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.